Suzhou Regend Therapeutics

Regend Therapeutics is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in regenerative medicine for respiratory diseases. The company leverages its proprietary lung stem cell platform to develop autologous cell therapies aimed at repairing damaged lung tissue. Their lead program involves the isolation, expansion, and transplantation of p63+ KRT5+ lung stem cells to treat conditions such as Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF). Regend's approach focuses on functional restoration of the respiratory system rather than just symptom management. The company has successfully advanced multiple programs into clinical trials, demonstrating a commitment to addressing high unmet medical needs in pulmonary health.